Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Base-Edited HSPC Gene Therapy for CXCR4-WHIM
NCT07775313Phase 2Enrolling by invitation
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in WHIM syndrome (WHIM), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 2 years. Started Oct 2026; status: enrolling by invitation.
02
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT07775313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07775313.